GUNJAN KUMAR: Open Payments
NPI 1518963412 · HACKENSACK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 23 payments from 12 companies in 2025. Trend: 2023 $46 · 2024 $0 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $135 |
| ABBVIE INC. | 6 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Janssen Biotech, Inc. | 2 | $32 |
| VIVUS LLC | 2 | $31 |
| Novo Nordisk Inc | 2 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: XIFAXAN, RINVOQ, ENTYVIO, ZENPEP, TREMFYA, Wegovy, CLENPIQ, SKYRIZI.
Industry payments across NJ — which companies pay providers there.
